



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Huang, et al.

Title:

METHODS AND

COMPOSITIONS FOR THE

AMPLIFICATION OF MUTATIONS IN THE DIAGNOSIS OF CYSTIC

FIBROSIS

Appl. No.:

10/775,650

Filing Date:

02/09/2004

Examiner:

Unknown

Art Unit:

1637

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Attn: Appl. Processing Division, Customer Correction Branch

Sir:

Attached is a copy of the official Filing Receipt received from the PTO in the above-referenced application.

There is an error with respect to one of the inventors' names. The name should read: Feras Hantash (Dana Point, CA);

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class

Mail in an envelope addressed to: Commissioner for Patents, P.O.

The Given Name was spelled incorrectly on the Application Data Sheet. A Supplemental Application Data Sheet is also enclosed herewith showing the correct spelling of the Given Name. Issuance of a corrected Filing Receipt is respectfully requested.

Although no fees are believed to be due, the Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 CFR §§ 1.16-1.17 to Deposit Account No. 50-0872.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 30542

Telephone:

(858) 847-6722

Facsimile:

(858) 792-6773

Barry S. Wilson

Attorney for Applicant

Registration No. 39,431

BEST AVAILABLE COPY

Page 1 of 2



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Sex 1450 Alexandra, Viginis 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/775,650	02/09/2004	1637	1198	034827-1502	1	27	5
1				J		, 🗸	\sim

CONFIRMATION NO. 3526

30542 FOLEY & LARDNER P.O. BOX 80278 SAN DIEGO, CA 92138-0278 FILING RECEIPT

OC000000012598655

Date Mailed: 05/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Doug Hui Huang, Aliso Viejo, CA; Feres Hantash, Dana Point, CA; Ronald Kagan, Mission Viejo, CA;

Assignment For Published Patent Application

Quest Diagnostics Incorporated;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/659,582 09/09/2003 🗸

Foreign Applications

If Required, Foreign Filing License Granted: 05/11/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

MAY 1 7 2004

RECEIVED

I.P. DEPT. FOLEY & LARONER

MAY 1 7 2004

Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis 🗸

BEST AVAILABLE COPY

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).